Granite Investment Partners LLC increased its stake in shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) by 22.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 111,344 shares of the specialty pharmaceutical company’s stock after buying an additional 20,354 shares during the period. Granite Investment Partners LLC owned 0.73% of Eagle Pharmaceuticals worth $6,641,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of EGRX. State of Alaska Department of Revenue lifted its position in Eagle Pharmaceuticals by 78.9% during the 2nd quarter. State of Alaska Department of Revenue now owns 1,592 shares of the specialty pharmaceutical company’s stock worth $125,000 after buying an additional 702 shares in the last quarter. Municipal Employees Retirement System of Michigan lifted its position in Eagle Pharmaceuticals by 6.7% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 1,910 shares of the specialty pharmaceutical company’s stock worth $151,000 after buying an additional 120 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in Eagle Pharmaceuticals by 58.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,456 shares of the specialty pharmaceutical company’s stock worth $194,000 after buying an additional 908 shares in the last quarter. Bank of Montreal Can lifted its position in Eagle Pharmaceuticals by 323.9% during the 2nd quarter. Bank of Montreal Can now owns 2,497 shares of the specialty pharmaceutical company’s stock worth $197,000 after buying an additional 1,908 shares in the last quarter. Finally, Campbell Newman Asset Management Inc. lifted its position in Eagle Pharmaceuticals by 4.9% during the 2nd quarter. Campbell Newman Asset Management Inc. now owns 2,693 shares of the specialty pharmaceutical company’s stock worth $212,000 after buying an additional 126 shares in the last quarter.

Several brokerages recently issued reports on EGRX. ValuEngine upgraded shares of Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Mizuho reiterated a “sell” rating and set a $37.00 price target on shares of Eagle Pharmaceuticals in a research report on Wednesday, November 8th. BidaskClub upgraded shares of Eagle Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 12th. Royal Bank Of Canada reiterated an “outperform” rating and set a $75.00 price target (down previously from $81.00) on shares of Eagle Pharmaceuticals in a research report on Thursday, November 9th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $75.00 target price on shares of Eagle Pharmaceuticals in a research report on Friday, October 27th. Three investment analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $62.33.

COPYRIGHT VIOLATION WARNING: This news story was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/granite-investment-partners-llc-raises-position-in-eagle-pharmaceuticals-inc-egrx/1717971.html.

Eagle Pharmaceuticals, Inc. (EGRX) traded down $0.45 during trading on Tuesday, reaching $56.40. 33,500 shares of the company’s stock were exchanged, compared to its average volume of 345,352. The company has a current ratio of 5.30, a quick ratio of 5.15 and a debt-to-equity ratio of 0.26. Eagle Pharmaceuticals, Inc. has a 52 week low of $45.05 and a 52 week high of $97.15. The firm has a market cap of $855.46, a P/E ratio of 9.05 and a beta of 1.23.

Eagle Pharmaceuticals declared that its board has initiated a share repurchase plan on Wednesday, August 9th that allows the company to buyback $100.00 million in outstanding shares. This buyback authorization allows the specialty pharmaceutical company to repurchase up to 13.3% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s management believes its stock is undervalued.

Eagle Pharmaceuticals Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.